Clare L. Crisp
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Clare L. Crisp has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Arshnoor Kaur
Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia
2 shared publications- Benjamin Leo Parker
The University of Melbourne
2 shared publications - Eleanor Glancy
Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia
2 shared publications - Janith A. Seneviratne
Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia
2 shared publications - Katie A. Fennell
Peter MacCallum Cancer Centre, Melbourne, Australia
2 shared publications - Marian L. Burr
The John Curtin School of Medical Research, The Australian National University, Canberra, Australian Capital Territory 2601, Australia
2 shared publications
Latest Publications
- Open Access
- 20 March 2026
- Published by Cold Spring Harbor Laboratory in Genes & Development
- Vol. 40 (9-10) , 756-776
Embryonic stem cell factors DPPA2/4 amplify active H3K4me3–H2AK119ub chromatin domains in non-small cell lung cancer
Embryonic regulators are often re-expressed in cancers; however, the functional and molecular significance of this is not always understood. The epigenetic priming factors developmental pluripotency-associated 2 and 4 (DPPA2/4) have crucial roles in early development and are implicated in cancer pathogenesis. We reveal that in non-small cell lung cancer (NSCLC), DPPA2/4 coexpression is associated with poorly differentiated tumors and impaired patient outcomes. Biochemically, human DPPA2/4 multimerize for their protein stability and enhanced nucleosome binding activity. In NSCLC cells, DPPA2/4 bind CG-rich sequences including promoters of developmental genes, Wnt signaling, and catabolic genes. Chromatin state modeling revealed that DPPA2/4 preferentially bind active H3K4me3 and H3K27ac domains that were intriguingly also enriched for PRC1 and its product, H2AK119ub, which was validated by H3K4me3–H2AK119ub sequential ChIP. Knockdown experiments revealed that DPPA2/4 were required to maintain RING1B and H2AK119ub at these domains. Surprisingly, despite the presence of PRC2.1, these regions lacked any detectable H3K27me3, suggesting an uncoupling between the recruitment of PRC2 to chromatin and its catalytic product. When exogenously overexpressed in NSCLC cells where they are not normally present, DPPA2/4 bind to and promote active chromatin states, resulting in an increase in in vivo xenograft tumor growth. Our results demonstrate how, in NSCLC cells, DPPA2/4 act as molecular amplifiers of active and poised chromatin. Together, this highlights how aberrant reactivation of embryonic factors in cancers may take on new functions, promoting tumorigenesis.
- 20 March 2026
- Published by Cold Spring Harbor Laboratory in Genes & Development
- Vol. 40 (9-10) , 756-776
Open AccessEmbryonic stem cell factors DPPA2/4 amplify active H3K4me3–H2AK119ub chromatin domains in non-small cell lung cancer
Embryonic regulators are often re-expressed in cancers; however, the functional and molecular significance of this is not always understood. The epigenetic priming factors developmental pluripotency-associated 2 and 4 (DPPA2/4) have crucial roles in early development and are implicated in cancer pathogenesis. We reveal that in non-small cell lung cancer (NSCLC), DPPA2/4 coexpression is associated with poorly differentiated tumors and impaired patient outcomes. Biochemically, human DPPA2/4 multimerize for their protein stability and enhanced nucleosome binding activity. In NSCLC cells, DPPA2/4 bind CG-rich sequences including promoters of developmental genes, Wnt signaling, and catabolic genes. Chromatin state modeling revealed that DPPA2/4 preferentially bind active H3K4me3 and H3K27ac domains that were intriguingly also enriched for PRC1 and its product, H2AK119ub, which was validated by H3K4me3–H2AK119ub sequential ChIP. Knockdown experiments revealed that DPPA2/4 were required to maintain RING1B and H2AK119ub at these domains. Surprisingly, despite the presence of PRC2.1, these regions lacked any detectable H3K27me3, suggesting an uncoupling between the recruitment of PRC2 to chromatin and its catalytic product. When exogenously overexpressed in NSCLC cells where they are not normally present, DPPA2/4 bind to and promote active chromatin states, resulting in an increase in in vivo xenograft tumor growth. Our results demonstrate how, in NSCLC cells, DPPA2/4 act as molecular amplifiers of active and poised chromatin. Together, this highlights how aberrant reactivation of embryonic factors in cancers may take on new functions, promoting tumorigenesis.
- Open Access
Embryonic stem cell factors DPPA2/4 facilitate a unique chromatin state in non-small cell lung cancer
Summary: Embryonic regulators are often re-expressed in cancers, however the functional and molecular significance of this is not always understood. The epigenetic priming factors Developmental Pluripotency Associated 2 and 4 (DPPA2/4) have crucial roles in early development and are implicated in cancer pathogenesis. We reveal in non-small cell lung cancer (NSCLC), DPPA2/4 co-expression is associated with poorly differentiated tumours, impaired patient outcomes and accelerated in vivo xenograft tumour growth. Proteomic analyses reveal DPPA2/4 dimerise to enhance their protein stability and binding efficiency to nucleosomes. Our multiomic epigenomic analysis uncovered novel functions for DPPA2/4 in facilitating a unique chromatin landscape in NSCLC cells at active promoters and enhancers. These domains are simultaneously marked by active H3K4me3, PRC1 deposited H2AK119Ub but devoid of PRC2 deposited H3K27me3. This paradoxical uncoupling between the activity of the Polycomb Repressive Complexes is likely driven by H3K27ac at these regions that prevents PRC2 catalytic activity but not recruitment. Our results demonstrate how in NSCLC cells, DPPA2/4 promote a “poised for repression” chromatin state, uncoupling complex recruitment from catalytic activity. Our study highlights how aberrant re-activation of embryonic factors in cancers may take on new functions, promoting tumourigenesis.
Open AccessEmbryonic stem cell factors DPPA2/4 facilitate a unique chromatin state in non-small cell lung cancer
Summary: Embryonic regulators are often re-expressed in cancers, however the functional and molecular significance of this is not always understood. The epigenetic priming factors Developmental Pluripotency Associated 2 and 4 (DPPA2/4) have crucial roles in early development and are implicated in cancer pathogenesis. We reveal in non-small cell lung cancer (NSCLC), DPPA2/4 co-expression is associated with poorly differentiated tumours, impaired patient outcomes and accelerated in vivo xenograft tumour growth. Proteomic analyses reveal DPPA2/4 dimerise to enhance their protein stability and binding efficiency to nucleosomes. Our multiomic epigenomic analysis uncovered novel functions for DPPA2/4 in facilitating a unique chromatin landscape in NSCLC cells at active promoters and enhancers. These domains are simultaneously marked by active H3K4me3, PRC1 deposited H2AK119Ub but devoid of PRC2 deposited H3K27me3. This paradoxical uncoupling between the activity of the Polycomb Repressive Complexes is likely driven by H3K27ac at these regions that prevents PRC2 catalytic activity but not recruitment. Our results demonstrate how in NSCLC cells, DPPA2/4 promote a “poised for repression” chromatin state, uncoupling complex recruitment from catalytic activity. Our study highlights how aberrant re-activation of embryonic factors in cancers may take on new functions, promoting tumourigenesis.